Novo Nordisk's long-acting growth hormone Phase III study successful. Sogroya improves children's yearly growth rate with once weekly dose.

According to the Securities Times APP, on May 12, Novo Nordisk (NVO.US) announced the data of the Phase III REAL8 basket trial, which showed that Sogroya (pasireotide) given once a week was comparable to daily growth hormone Norditropin (somatropin) in improving the annual growth rate of prepubescent children with small for gestational age (SGA), Noonan syndrome (NS), and idiopathic short stature (ISS) (measured by height velocity at 52 weeks). In addition, Sogroya was superior to daily growth hormone in children with Noonan syndrome (NS), and in children with small for gestational age (SGA), Sogroya was also superior to daily low-dose growth hormone.